AzTrials
AzTrials

Physical ActivityEIMNCT03416634

Exercise is Medicine at Emory Seavey Internal Medicine Clinic

A study testing App, Wearable Device and Automated Motivational Message in people with Physical Activity, run by Emory University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Implementation of physical activity promotion in routine health care delivery is low because of multiple barriers including insufficient health system support, care team coordination, and scarcity of community resources for referring patients and technology tools for sustaining lifestyle changes. Read more about this study

Who is it for?
Ages 20 to 80 years
Conditions the study is for
Physical Activity
What is being tested?
App, Wearable Device and Automated Motivational Message
Could I receive a placebo?
No, everyone receives an active treatment
How many people
106 participants
Where
1 siteUnited States
Study dates
20 Aug 2018to 1 Feb 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • At least one documented cardiovascular disease risk factor
  • Not meeting physical activity (PA) guidelines (aerobic and/or muscle-strengthening standards)
  • contemplating PA engagement
  • Non-wheelchair bound (other assist devices will be acceptable) or major physical limitations for PA
  • Cleared for independent PA by their health care provider
  • Willingness to participate and provide written informed consent
  • Report access to a mobile phone with data plan and/or computer with internet access
  • Agrees to not own/use a different PA wearable device during the study period.

Who cannot join

  • Documented unstable angina or myocardial infarction in the past 3 months without having finalized an initial cardiac rehabilitation program;
  • Documented end-stage renal disease or life-threatening disease;
  • Diagnosed major mental health disorder;
  • Alcohol or drug abuse.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Paul W. Seavey Internal Medicine Clinic

    Atlanta, Georgia, 30322

Other trials in United States

About this study

Official title: Exercise is Medicine (EIM): A Quality Improvement and Pragmatic Trial at Emory Seavey Internal Medicine Clinic

Implementation of physical activity promotion in routine health care delivery is low because of multiple barriers including insufficient health system support, care team coordination, and scarcity of community resources for referring patients and technology tools for sustaining lifestyle changes. This study is a pilot project to test the feasibility of implementing a physical activity promotion protocol, including routine evaluation of patient's physical activity levels and provision of educational material in the clinical workflow. Physically inactive adult patients with at least one documented cardiovascular disease risk factor will be invited to participate in physical activity intervention. Patients will be randomized to receive a wearable device or a smartphone app to objectively monitor their physical activity. Participants will be further randomized to receive automated motivational text messages, or a personalized motivational message, or no messages. Participants will be followed through the 12 week intervention period and an additional 12 weeks with no intervention.

Read the detailed description

Improving and maintaining health-enhancing levels of physical activity (PA) leads to reductions in the metabolic, hemodynamic, body composition, epi-genetic and functional status risk factors that heavily contribute to the development of many non-communicable chronic diseases. As such, PA has a significant role, in many cases comparable or superior to drug interventions, in the prevention and treatment of more than 40 diseases such as obesity, heart disease, diabetes, hypertension, cancer, depression, anxiety, arthritis, and osteoporosis.

While conceptually simple, implementing clinical-community linkages for PA promotion is hindered by barriers at multiple levels such as inadequate training and self-efficacy among health care providers (HCPs), insufficient health system support and care team coordination, and scarcity of certified community resources for referring patients. The challenge for HCPs and health systems is how to operationalize, standardize, and implement PA promotion in a cost-effective and innovative fashion.

This study is a pilot project to test the feasibility of implementing a physical activity promotion protocol including routine evaluation of patient's physical activity levels and provision of educational material in the clinical workflow of the Seavey Internal Medicine Clinic at Emory University. Physically inactive adult patients with at least one documented cardiovascular disease risk factor (overweight/obesity, dyslipidemia, hypertension, diabetes) but cleared for self-directed exercise by their treating clinician will be invited to participate in physical activity intervention. Patients will be randomized to receive a wearable device (Garmin vivofit 3) or a smartphone app (Microsoft Band) to objectively monitor their physical activity. Participants will be further randomized to receive automated motivational text messages, or a personalized motivational message, or no messages. Participants will be followed through the 12 week intervention period and an additional 12 weeks with no intervention. The researchers will assess changes in objectively-measured physical activity (primary outcome) and explore impact on secondary outcomes including cardiovascular disease (CVD) risk factors (assessed routinely as part of clinical management), as well as self-reported mental health, quality of life and exercise self-efficacy using validated questionnaires.

Being tested
App, Wearable Device, Automated Motivational Message, Personalized Motivational Message
Keywords
Health promotion, Behavioral research, Preventive medicine, Obesity, Cardiovascular disease
Medical subject headings
Motor Activity, Obesity, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AppBehavioural

    The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.

  • Wearable DeviceBehavioural

    A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.

  • Automated Motivational MessageBehavioural

    An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.

  • Personalized Motivational MessageBehavioural

    A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.

Study groups in NCT03416634
Study groupRoleWhat they receive
App AloneActive comparatorParticipants randomized to use the Microsoft Band app to track daily activity
Receives: Behavioral: App
App Plus Automated Motivational MessageExperimentalParticipants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
Receives: Behavioral: App; Behavioral: Automated Motivational Message
App Plus Personalized Motivational MessageExperimentalParticipants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
Receives: Behavioral: App; Behavioral: Personalized Motivational Message
Wearable Device AloneActive comparatorParticipants randomized to use the Garmin vivofit 3 wearable device to track daily activity
Receives: Behavioral: Wearable Device
Wearable Device Plus Automated Motivational MessageExperimentalParticipants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
Receives: Behavioral: Wearable Device; Behavioral: Automated Motivational Message
Wearable Device Plus Personalized Motivational MessageExperimentalParticipants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
Receives: Behavioral: Wearable Device; Behavioral: Personalized Motivational Message

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Physical Activity

    Physical activity will be measured through the Microsoft Band app or with the Garmin vivofit 3. The physical activity of the participants will be monitored during the 12 week intervention period (when some study arms will receive motivational messages) and through 12 additional weeks of follow up.

    Measured: Baseline through Week 24

Secondary outcomes (13)
  1. Change in weight

    Weight in kilograms will be measured at baseline and throughout the study period.

    Measured: Baseline through Week 24

  2. Change in triglycerides

    The cardiovascular disease risk factor of dyslipidemia will be assessed by measuring triglycerides at baseline and throughout the study period. Triglycerides above 150 mg/dL are considered high.

    Measured: Baseline through Week 24

  3. Change in total cholesterol

    The cardiovascular disease risk factor of dyslipidemia will be assessed by measuring total cholesterol at baseline and throughout the study period. Total cholesterol above 200 mg/dL is considered high.

    Measured: Baseline through Week 24

  4. Change in hypertension status

    The cardiovascular disease risk factor of hypertension will be assessed by measuring blood pressure at baseline and throughout the study period. Blood pressure will be measured as systolic and diastolic millimeters of mercury (mmHg). A blood pressure reading of 140/90 mmHg for a sustained period is considered hypertension.

    Measured: Baseline through Week 24

  5. Change in blood glucose

    Blood glucose levels will be measured at baseline and throughout the study. Normal fasting blood glucose levels are between 70 and 100 mg/dL.

    Measured: Baseline through Week 24

  6. Change in hemoglobin A1c (HbA1c)

    HbA1c levels will be measured at baseline and throughout the study. The normal range for HbA1c levels is between 4% and 5.6% of total hemoglobin. Diabetes is diagnosed if HbA1c is greater than 6.5%.

    Measured: Baseline through Week 24

  7. Change in Center for Epidemiologic Studies Depression Scale (CES-D) Score

    Symptoms of depression will be measured with the Center for Epidemiologic Studies Depression Scale (CES-D), National Institute of Mental Health (NIMH). The CES-D asks respondents to indicate how they have felt or behaved in the past week to 20 symptoms of depression, such as "My sleep was restless" and "I was happy". Participants will select from Rarely (<1 day), Some of the time (1-2 days), Occasionally (3-4 days) and Most of the time (5-7 days). Responses are scored from 0 to 3, with reverse scoring for positive items so that 0 corresponds with low symptoms. Total possible scores range from 0 to 60, with higher scores indicating increased symptoms of depression.

    Measured: Baseline, Week 12, Week 24

  8. Change in Eating Habits Confidence Survey Score

    Self-efficacy to make dietary changes will be measured with the Eating Habits Confidence Survey. This survey asks participants to rate how confident they are that they could motivate themselves to make certain dietary changes for 6 months. The 20-item survey includes statements such as "Eat smaller portions at dinner" and respondents indicate how sure they can do each item on a 5 point scale where 1 = "I know I cannot" and 5 = "I know I can". Total scores range from 20 to 100, where higher scores indicate increased confidence in making dietary changes.

    Measured: Baseline, Week 12, Week 24

  9. Change in Exercise Confidence Survey Score

    Self-efficacy to make changes in exercise habits will be measured with the Exercise Confidence Survey. This survey asks participants to rate how confident they are that they could motivate themselves to make certain changes to physical activity habits for 6 months. The 12-item survey includes statements such as "Get up early, even on weekends, to exercise" and respondents indicate how sure they can do each item on a 5 point scale where 1 = "I know I cannot" and 5 = "I know I can". Total scores range from 12 to 60, where higher scores indicate increased confidence in making changes to exercise habits.

    Measured: Baseline, Week 12, Week 24

  10. Change in Social Support and Exercise Survey Score

    The Social Support and Exercise Survey assesses how much support the respondent receives from family members and friends. Participants will rate how often each of the 13 incidents specified occurred in the last three months, rating family and friends separately. Each item is rated on a scale of 1 to 5 where 1 = none and 5 = very often. The responses will be summed to obtain an overall score of the support received from family and friends. Total scores can range from 26 to 130. Scores for particular items are scored in reverse so that higher scores indicate more support.

    Measured: Baseline, Week 12, Week 24

  11. Change in Short-Form Patient Satisfaction Questionnaire (PSQ-18) Score

    The Short-Form Patient Satisfaction Questionnaire (PSQ-18) asks respondents how much they agree with statements related to the medical care they receive. The 18-item questionnaire includes statements such as "Doctors are good about explaining the reason for medical tests" and "Doctors sometimes ignore what I tell them". Each item is rated from 1 (strongly agree) to 5 (disagree). All items are scored so that high scores reflect satisfaction with medical care. Total scores can range from 18 to 90.

    Measured: Baseline, Week 12, Week 24

  12. Change in 12-Item Short-Form Health Survey (SF-12) Score

    The 12-Item Short-Form Health Survey (SF-12) asks respondents to rate their health and abilities to do their usual tasks. The SF-12 uses a variety of questions and response options and includes a physical health component summary and a mental health component summary. Scores are reversed, when appropriate, so that a higher value indicates better health. The scale is transformed to have a mean of 50 and a standard deviation of 10; scores above 50 indicate better health than the general US population, while scores below 50 indicate poorer than average health.

    Measured: Baseline, Week 12, Week 24

  13. Change in 36-Item Short-Form Health Survey (SF-36) Score

    The 36-Item Short-Form Health Survey (SF-36) asks respondents to rate their health and abilities to do their usual tasks. The SF-36 uses a variety of questions and response options and includes 8 subscales (physical functioning, role limitations due to physical health, role limitations due to emotional health, energy/fatigue, emotional well-being, social functioning, pain, and general health). Responses are coded on a scale of 0 to 100 where 0 is the worst possible health and 100 is the most favorable health score. The coded responses will be summed and averaged to obtain a mean score for the entire survey.

    Measured: Baseline, Week 12, Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2018
  2. Study start20 Aug 2018
  3. Primary completion1 Feb 2020
  4. Study completion1 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Factorial
Model description
90 participants will use a wearable device and 90 will use a smartphone app to track activity. These groups will be further randomized to receive an automated motivational intervention, or a personalized motivational intervention or no additional intervention; each study arm will have 30 participants.
Masking
None (open label)
Enrolment
106 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03416634
Sponsor's protocol ID
IRB00101370
Acronym
EIM
Status last verified
Feb 2020
First submitted
24 Jan 2018
Last updated
19 Feb 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing App, Wearable Device and Automated Motivational Message in people with Physical Activity, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Physical Activity (time frame: Baseline through Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
EIM Clinical Trial NCT03416634 | AzTrials